With multiple companies looking to address treatment shortcomings in chronic spontaneous urticaria (CSU) with standard of care Xolair, Celldex Therapeutics, Inc. presented Phase II data at the American Academy of Allergy, Asthma and Immunology annual meeting on 25 February that some analysts said suggest a best-in-class profile for the disease. Celldex is planning to take its drug, barzolvolimab, a binder of receptor tyrosine kinase KIT, into Phase III for CSU later this year, while awaiting 52-week data from the Phase II study.
Celldex May Have Best Efficacy In Chronic Spontaneous Urticaria
Sanofi Also Succeeds With BTKi In Phase II
Looking to treat patients with CSU uncontrolled by Xolair, Celldex’s KIT binder barzolvolimab shows strong disease activity reduction at 12 weeks in Phase II. Sanofi’s BTK inhibitor rilzabrutinib also showed efficacy in CSU.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.